Firefly Bio Acquired by Johnson & Johnson | Healthcare M&A Deal

Johnson & Johnson has acquired Firefly Bio, a healthcare services other business in New Jersey, for $1B. Firefly Bio focuses on oncology-related research and pipeline development, supporting Johnson & Johnson’s efforts to expand cancer programs. The Firefly Bio acquisition strengthens Johnson & Johnson acquisitions in healthcare M&A, adding capabilities aligned with strategic oncology growth. This strategic acquisition is structured as a platform acquisition and is categorized as healthcare M&A and NJ acquisitions, with deal status announced and size over $100M.